<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39390548</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1476-0711</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>10</Day></PubDate></JournalIssue><Title>Annals of clinical microbiology and antimicrobials</Title><ISOAbbreviation>Ann Clin Microbiol Antimicrob</ISOAbbreviation></Journal><ArticleTitle>The evaluation of SARS-CoV-2 mutations at the early stage of the pandemic in Istanbul population.</ArticleTitle><Pagination><StartPage>93</StartPage><MedlinePgn>93</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">93</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12941-024-00750-y</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Determination of SARS-CoV-2 variant is significant to prevent the spreads of COVID-19 disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We aimed to evaluate the variants of SARS-CoV-2 rate in positive patients in Kanuni Sultan Suleyman Training and Research Hospital (KSS-TRH), Istanbul, Türkiye between 1st January and 30th November 2021 by using RT-PCR method.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Herein, 825,169 patients were evaluated (male:58.53% and female:41.47%) whether COVID-19 positive or not [( +):21.3% and (-):78.7%] and 175,367 patient was described as positive (53.2%-female and 46.8%-male) by RT-PCR. COVID-19 positive rate is observed highest in the 6-15- and 66-75-year age range. The frequencies were obtained as SARS-CoV-2 positive (without mutation of B.1.1.7 [B.1.1.7 (U.K), E484K, L452R, B.1.351 (S. Africa/Brazil) spike mutations] as 66.1% (n: 115,899), B.1.1.7 Variant as 23.2% (n:40,686), Delta mutation (L452R) variant as 9.8% (n:17,182), B.1.351 variant as 0.8% (n:1370) and E484K as 0.1% (n: 230). In April 2021, general SARS-CoV-2 and B.1.1.7 variant were dominantly observed. Up to July 2021, B.1.617.2 (Delta variant/ Indian variant) and E484K has been not observed. B.1.351 variant of SARS-CoV-2 has been started in February 2021 at the rarest ratio and March 2021 is the top point. September 2021 is the pick point of E484K. African/Brazil variant of SARS-CoV-2 has been started in February 2021 at the rarest ratio and March 2021 is the top point. September 2021 is the pick point of E484K. When the gender type is compared within the variants, women were found to be more prevalent in all varieties.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The meaning of these mutations is very important to understand the transmission capacity of the COVID-19 disease, pandemic episode, and diagnosis of the virus with mutation types. Understanding the variant type is important for monitoring herd immunity and the spread of the disease.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Uyar</LastName><ForeName>Yavuz</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-4923-7928</Identifier><AffiliationInfo><Affiliation>Cerrahpaşa Faculty of Medicine, Department of Medical Microbiology, Istanbul University-Cerrahpaşa, 34147, Istanbul, Türkiye. yavuz.uyar@iuc.edu.tr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart Kömürcü</LastName><ForeName>Selen Zeliha</ForeName><Initials>SZ</Initials><Identifier Source="ORCID">0000-0001-7500-0783</Identifier><AffiliationInfo><Affiliation>Republic of Türkiye, Istanbul Provincial Directorate of Health, Ministry of Health, University of Health Science, Kanuni Sultan Suleyman Training and Research Hospital, Kücükcekmece, 34303, Istanbul, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Artik</LastName><ForeName>Yakup</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-2636-4879</Identifier><AffiliationInfo><Affiliation>Health Institutes of Türkiye (TUSEB), COVID-19 Diagnostic Center, Istanbul Provincial Directorate of Health, Republic of Türkiye Ministry of Health, University of Health Science, Kanuni Sultan Suleyman Training and Research Hospital, Kücükcekmece, 34303, Istanbul, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cesur</LastName><ForeName>Nevra Pelin</ForeName><Initials>NP</Initials><Identifier Source="ORCID">0000-0003-3979-6053</Identifier><AffiliationInfo><Affiliation>Health Institutes of Türkiye (TUSEB), COVID-19 Diagnostic Center, Istanbul Provincial Directorate of Health, Republic of Türkiye Ministry of Health, University of Health Science, Kanuni Sultan Suleyman Training and Research Hospital, Kücükcekmece, 34303, Istanbul, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanrıverdi</LastName><ForeName>Arzu</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-4707-4456</Identifier><AffiliationInfo><Affiliation>Republic of Türkiye, Istanbul Provincial Directorate of Health, Ministry of Health, University of Health Science, Kanuni Sultan Suleyman Training and Research Hospital, Kücükcekmece, 34303, Istanbul, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Şanlı</LastName><ForeName>Kamuran</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-0814-5637</Identifier><AffiliationInfo><Affiliation>Republic of Türkiye, Istanbul Provincial Directorate of Health, Ministry of Health, University of Health Science, Başakşehir Çam and Sakura City Hospital, Başakşehir, 34480, Istanbul, Türkiye.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Clin Microbiol Antimicrob</MedlineTA><NlmUniqueID>101152152</NlmUniqueID><ISSNLinking>1476-0711</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014421" MajorTopicYN="N" Type="Geographic">Turkey</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Delta</Keyword><Keyword MajorTopicYN="N">Epsilon</Keyword><Keyword MajorTopicYN="N">Kappa</Keyword><Keyword MajorTopicYN="N">Mutation</Keyword><Keyword MajorTopicYN="N">RT‐PCR</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>0</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>23</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39390548</ArticleId><ArticleId IdType="pmc">PMC11468081</ArticleId><ArticleId IdType="doi">10.1186/s12941-024-00750-y</ArticleId><ArticleId IdType="pii">10.1186/s12941-024-00750-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–74. 10.1016/S0140-6736(20)30251-8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159086</ArticleId><ArticleId IdType="pubmed">32007145</ArticleId></ArticleIdList></Reference><Reference><Citation>Salzberger B, Buder F, Lampl B, Ehrenstein B, Hitzenbichler F, Holzmann T, Schmidt B, Hanses F. Epidemiology of SARS-CoV-2. Infection. 2021;49(2):233–9. 10.1007/s15010-020-01531-3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7543961</ArticleId><ArticleId IdType="pubmed">33034020</ArticleId></ArticleIdList></Reference><Reference><Citation>Artik Y, Varol N, Cesur NP. Hospital disaster and emergency plan in biological disasters (HDEP): coronavirus (SARS-CoV-2) COVID-19 pandemic system model example. J Contemp Stud Epidemiol Public Health. 2022;3(1): ep22003. 10.29333/jconseph/11975.</Citation></Reference><Reference><Citation>Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433. 10.1016/j.jaut.2020.102433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7127067</ArticleId><ArticleId IdType="pubmed">32113704</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Gao J, Luo X, Feng L, Liu W, Chen J, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vertical transmission in neonates born to mothers with coronavirus disease 2019 (COVID-19) pneumonia. Obstet Gynecol. 2020;136(1):65–7. 10.1097/AOG.0000000000003926.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7219851</ArticleId><ArticleId IdType="pubmed">32332320</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents. 2020;55(5):105955. 10.1016/j.ijantimicag.2020.105955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7138178</ArticleId><ArticleId IdType="pubmed">32234468</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh KA, Jordan K, Clyne B, Rohde D, Drummond L, Byrne P, et al. SARS-CoV-2 detection, viral load and infectivity over the course of an infection. J Infect. 2020;81(3):357–71. 10.1016/j.jinf.2020.06.067.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7323671</ArticleId><ArticleId IdType="pubmed">32615199</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO World Health Organization. Coronavirus (COVID-19) Dashboard. https://covid19.who.int/. Accessed 26 Feb 2022.</Citation></Reference><Reference><Citation>Çagdaş D. Living the SARS-CoV-2 pandemic in Turkey. Nat Immunol. 2021;22:256–61.</Citation><ArticleIdList><ArticleId IdType="pubmed">33627882</ArticleId></ArticleIdList></Reference><Reference><Citation>Artik Y, Coşğun AB, Cesur NP, Hızel N, Uyar Y, Sur H, et al. Comparison of COVID-19 laboratory diagnosis by commercial kits: effectivity of RT-PCR to the RT-LAMP. J Med Virol. 2022;94(5):1998–2007. 10.1002/jmv.27559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9015626</ArticleId><ArticleId IdType="pubmed">34997587</ArticleId></ArticleIdList></Reference><Reference><Citation>Barlas G, Öztürk H, Pehlivantürk G, Aydin S. Turkey’s response to COVID-19 pandemic: strategy and key actions. Turk J Med Sci. 2021;51:3150–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">34365784</ArticleId></ArticleIdList></Reference><Reference><Citation>Turkish Ministry of Health (T.C. Sağlık Bakanlığı) Coronavirus (COVID-19). https://covid19.saglik.gov.tr/. Accessed 15 Apr 2024.</Citation></Reference><Reference><Citation>Safer M, Letaief H, Hechaichi A, Harizi C, Dhaouadi S, Bouabid L, et al. Identification of transmission chains and clusters associated with COVID-19 in Tunisia. BMC Infect Dis. 2021;21(1):453. 10.1186/s12879-021-06107-6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8132040</ArticleId><ArticleId IdType="pubmed">34011266</ArticleId></ArticleIdList></Reference><Reference><Citation>Padhi AK, Tripathi T. Can SARS-CoV-2 accumulate mutations in the S-protein to increase pathogenicity? ACS Pharmacol Transl Sci. 2020;3(5):1023–6. 10.1021/acsptsci.0c00113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7551720</ArticleId><ArticleId IdType="pubmed">33073197</ArticleId></ArticleIdList></Reference><Reference><Citation>Martínez-Anaya C, Ramos-Cervantes P, Vidaltamayo R. Coronavirus, diagnosis and epidemiological strategies against COVID-19 in Mexico. Educ Quim. 2020;31:12–22.</Citation></Reference><Reference><Citation>Volz E, Hill V, McCrone JT, Price A, Jorgensen D, O’Toole Á, et al. Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity. Cell. 2021;184(1):64-75.e11. 10.1016/j.cell.2020.11.020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7674007</ArticleId><ArticleId IdType="pubmed">33275900</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng X, Gu W, Federman S, du Plessis L, Pybus OG, Faria N, et al. A genomic survey of SARS-CoV-2 reveals multiple introductions into Northern California without a predominant lineage. Science. 2020;369(6503):582–7. 10.1126/science.abb9263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7286545</ArticleId><ArticleId IdType="pubmed">32513865</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YZ, Holmes EC. A genomic perspective on the origin and emergence of SARS-CoV-2. Cell. 2020;181(2):223–7. 10.1016/j.cell.2020.03.035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7194821</ArticleId><ArticleId IdType="pubmed">32220310</ArticleId></ArticleIdList></Reference><Reference><Citation>Amanat F, Krammer F. SARS-CoV-2 vaccines: status report. Immunity. 2020;52(4):583–9. 10.1016/j.immuni.2020.03.007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7136867</ArticleId><ArticleId IdType="pubmed">32259480</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO World Health Organization. Weekly epidemiological update on COVID-19. 2021. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/. Accessed 15 Apr 2022.</Citation></Reference><Reference><Citation>WHO World Health Organization. Tracking SARS-CoV-2 variants. https://www.who.int/activities/tracking-SARS-CoV-2-variants. Accessed 20 Jan 2023.</Citation></Reference><Reference><Citation>Flores-Vega VR, Monroy-Molina JV, Jiménez-Hernández LE, Torres AG, Santos-Preciado JI, Rosales-Reyes R. SARS-CoV-2: evolution and emergence of new viral variants. Viruses. 2022;14(4):653. 10.3390/v14040653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9025907</ArticleId><ArticleId IdType="pubmed">35458383</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin E, Bozdayi G, Yigit S, Muftah H, Dizbay M, Tunccan OG, et al. Genomic characterization of SARS-CoV-2 isolates from patients in Turkey reveals the presence of novel mutations in spike and nsp12 proteins. J Med Virol. 2021;93(10):6016–26. 10.1002/jmv.27188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8426744</ArticleId><ArticleId IdType="pubmed">34241906</ArticleId></ArticleIdList></Reference><Reference><Citation>PANGO. Latest epidemiological lineages of SARS-CoV-2. 2022. https://cov-lineages.org/index.html. Accessed 15 Apr 2022.</Citation></Reference><Reference><Citation>Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, COVID-19 Genomics UK (COG-UK) consortium, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022;399(10332):1303–12. 10.1016/S0140-6736(22)00462-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8926413</ArticleId><ArticleId IdType="pubmed">35305296</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoteit R, Yassine HM. Biological properties of SARS-CoV-2 variants: epidemiological impact and clinical consequences. Vaccines. 2022;10:919.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9230982</ArticleId><ArticleId IdType="pubmed">35746526</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun C, Xie C, Bu GL, Zhong LY, Zeng MS. Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. Signal Transduct Target Ther. 2022;7(1):202. 10.1038/s41392-022-01039-2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9240077</ArticleId><ArticleId IdType="pubmed">35764603</ArticleId></ArticleIdList></Reference><Reference><Citation>Brant AC, Tian W, Majerciak V, Yang W, Zheng ZM. SARS-CoV-2: from its discovery to genome structure, transcription, and replication. Cell Biosci. 2021;11(1):136. 10.1186/s13578-021-00643-z.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8287290</ArticleId><ArticleId IdType="pubmed">34281608</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaqinuddin A, Shafqat A, Kashir J, Alkattan K. Effect of SARS-CoV-2 mutations on the efficacy of antibody therapy and response to vaccines. Vaccines. 2021;9(8):914. 10.3390/vaccines9080914.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8402590</ArticleId><ArticleId IdType="pubmed">34452039</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam S, Islam T, Islam MR. New coronavirus variants are creating more challenges to global healthcare system: a brief report on the current knowledge. Clin Pathol. 2022;15:2632010X221075584. 10.1177/2632010X221075584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8819824</ArticleId><ArticleId IdType="pubmed">35141522</ArticleId></ArticleIdList></Reference><Reference><Citation>Komurcu SZM, Artik Y, Cesur NP, Tanriverdi A, Erdogan DC, Celik S, et al. The evaluation of potential global impact of the N501Y mutation in SARS-COV-2 positive patients. J Med Virol. 2022;94(3):1009–19. 10.1002/jmv.27413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8661766</ArticleId><ArticleId IdType="pubmed">34676574</ArticleId></ArticleIdList></Reference><Reference><Citation>Artik Y, Cesur N, Kenar L, Ortatli M. Biological disasters: an overview of the Covid-19 pandemic in the first quarter of 2021. J Disaster Risk. 2021;4(2):163–82. 10.35341/AFET.977488.</Citation></Reference><Reference><Citation>Andrews HS, Herman JD, Gandhi RT. Treatments for COVID-19. Annu Rev Med. 2024;29(75):145–57. 10.1146/annurev-med-052422-020316.</Citation><ArticleIdList><ArticleId IdType="pubmed">37722709</ArticleId></ArticleIdList></Reference><Reference><Citation>Zafrullah M, Zhang X, Tran C, Nguyen M, Kamili S, Purdy MA, Stramer SL. Disparities in detection of antibodies against hepatitis E virus in US blood donor samples using commercial assays. Transfusion. 2018;58(5):1254–63. 10.1111/trf.14553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5912996</ArticleId><ArticleId IdType="pubmed">29520800</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet. 2021;22(12):757–73. 10.1038/s41576-021-00408-x.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8447121</ArticleId><ArticleId IdType="pubmed">34535792</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatirnaz Ng O, Akyoney S, Sahin I, Soykam HO, BayramAkcapinar G, Ozdemir O, et al. Mutational landscape of SARS-CoV-2 genome in Turkey and impact of mutations on spike protein structure. PLoS ONE. 2021;16(12): e0260438. 10.1371/journal.pone.0260438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8648120</ArticleId><ArticleId IdType="pubmed">34871297</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusof W, Irekeola AA, Wada Y, Engku Abd Rahman ENS, Ahmed N, et al. A global mutational profile of SARS-CoV-2: a systematic review and meta-analysis of 368,316 COVID-19 patients. Life. 2021;11(11):1224. 10.3390/life11111224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8620851</ArticleId><ArticleId IdType="pubmed">34833100</ArticleId></ArticleIdList></Reference><Reference><Citation>De Marco C, Marascio N, Veneziano C, Biamonte F, Trecarichi EM, Santamaria G, et al. Whole-genome analysis of SARS-CoV-2 in a 2020 infection cluster in a nursing home of Southern Italy. Infect Genet Evol. 2022;99:105253. 10.1016/j.meegid.2022.105253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8855624</ArticleId><ArticleId IdType="pubmed">35189404</ArticleId></ArticleIdList></Reference><Reference><Citation>Leducq V, Couturier J, Granger B, Jolivet S, Morand-Joubert L, Robert J, et al. Investigation of healthcare-associated COVID-19 in a large French hospital group by whole-genome sequencing. Microbiol Res. 2022;263:127133. 10.1016/j.micres.2022.127133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9306220</ArticleId><ArticleId IdType="pubmed">35901580</ArticleId></ArticleIdList></Reference><Reference><Citation>Artik Y, Mart Komurcu SZ, Kazezoglu C, Guner AE, Yilmaz H, Uyar Y. Evaluation of post-vaccination antibody response of biochemical analysis in SARS-CoV-2 inactivated vaccine strategy. J Contemp Stud Epidemiol Public Health. 2023;4(1): ep23005.</Citation></Reference><Reference><Citation>Guruprasad L. Human SARS CoV-2 spike protein mutations. Proteins. 2021;89(5):569–76. 10.1002/prot.26042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8014176</ArticleId><ArticleId IdType="pubmed">33423311</ArticleId></ArticleIdList></Reference><Reference><Citation>Artik Y, Cesur NP, Laçin NT. SARS-CoV-2 mutations, diagnosis and their concern. Arch Mol Biol Genet. 2022;1(2):57–65.</Citation></Reference><Reference><Citation>Kozłowski P, Leszczyńska A, Ciepiela O. Long COVID definition, symptoms, risk factors, epidemiology and autoimmunity: a narrative review. Am J Med Open. 2024;14(11):100068. 10.1016/j.ajmo.2024.100068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11256271</ArticleId><ArticleId IdType="pubmed">39034937</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern A, Fleishon S, Kustin T, Mandelboim M, Erster O. The unique evolutionary dynamics of the SARS-CoV-2 Delta variant. medRxiv. 2021. 10.1101/2021.08.05.21261642.</Citation></Reference><Reference><Citation>Plante JA, Liu Y, Liu J, Xia H, Johnson BA, Lokugamage KG, et al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature. 2021;592(7852):116–21. 10.1038/s41586-020-2895-3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8158177</ArticleId><ArticleId IdType="pubmed">33106671</ArticleId></ArticleIdList></Reference><Reference><Citation>Artik Y, Cesur NP. General evaluation of Covid-19 diagnosis methods. Cohesive J Microbiol Infect Dis. 2022;5(5): CJMI.000621. 10.31031/CJMI.2022.05.000621.</Citation></Reference><Reference><Citation>Kannan SR, Spratt AN, Quinn TP, Heng X, Lorson CL, Sönnerborg A, et al. Infectivity of SARS-CoV-2: there is something more than D614G? J Neuroimmune Pharmacol. 2020;15(4):574–7. 10.1007/s11481-020-09954-3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7490321</ArticleId><ArticleId IdType="pubmed">32930936</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley S, Wang H, Eales O, Haw D, Walters CE, Ainslie KEC, et al. REACT-1 round 12 report: resurgence of SARS-CoV-2 infections in England associated with increased frequency of the Delta variant. MedRxiv. 2021. 10.1101/2021.06.17.21259103.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Singanayagam A, Hakki S, Dunning J, Madon KJ, Crone MA, Koycheva A, et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. Lancet Infect Dis. 2022;22(2):183–95. 10.1016/S1473-3099(21)00648-4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8554486</ArticleId><ArticleId IdType="pubmed">34756186</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Davis BD, Chen SS, Sincuir Martinez JM, Plummer JT, Vail E. Emergence of a novel SARS-CoV-2 variant in southern California. JAMA. 2021;325(13):1324–6. 10.1001/jama.2021.1612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7879386</ArticleId><ArticleId IdType="pubmed">33571356</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Wu J, Nie J, Zhang L, Hao H, Liu S, et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell. 2020;182(5):1284-1294.e9. 10.1016/j.cell.2020.07.012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7366990</ArticleId><ArticleId IdType="pubmed">32730807</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbe S, Buckland-Merrett G. Data, disease and diplomacy: GISAID’s innovative contribution to global health. Glob Chall. 2017;1(1):33–46. 10.1002/gch2.1018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6607375</ArticleId><ArticleId IdType="pubmed">31565258</ArticleId></ArticleIdList></Reference><Reference><Citation>Saville JW, Mannar D, Zhu X, Srivastava SS, Berezuk AM, Demers JP, et al. Structural and biochemical rationale for enhanced spike protein fitness in delta and kappa SARS-CoV-2 variants. Nat Commun. 2022;13(1):742. 10.1038/s41467-022-28324-6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8826856</ArticleId><ArticleId IdType="pubmed">35136050</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzou PL, Tao K, Nouhin J, Rhee SY, Hu BD, Pai S, et al. Coronavirus antiviral research database (CoV-RDB): an online database designed to facilitate comparisons between candidate anti-coronavirus compounds. Viruses. 2020;12(9):1006. 10.3390/v12091006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7551675</ArticleId><ArticleId IdType="pubmed">32916958</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvatore M, Bhattacharyya R, Purkayastha S, Zimmermann L, Ray D, Hazra A, et al. Resurgence of SARS-CoV-2 in India: Potential role of the B.1.617.2 (Delta) variant and delayed interventions. MedRxiv. 2021. 10.1101/2021.06.23.21259405.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Beltran WF, Lam EC, St Denis K, Nitido AD, Garcia ZH, Hauser BM, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184(9):2372-2383.e2379. 10.1016/j.cell.2021.03.013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7953441</ArticleId><ArticleId IdType="pubmed">33743213</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen RE, Zhang X, Case JB, Winkler ES, Liu Y, VanBlargan LA, et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med. 2021;27(4):717–26. 10.1038/s41591-021-01294-w.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8058618</ArticleId><ArticleId IdType="pubmed">33664494</ArticleId></ArticleIdList></Reference><Reference><Citation>Collier DA, De Marco A, Ferreira IATM, Meng B, Datir RP, Walls AC, et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature. 2021;593(7857):136–41. 10.1038/s41586-021-03412-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">33706364</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med. 2020;27(2): taaa021. 10.1093/jtm/taaa021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7074654</ArticleId><ArticleId IdType="pubmed">32052846</ArticleId></ArticleIdList></Reference><Reference><Citation>Despres HW, Mills MG, Shirley DJ, Schmidt MM, Huang ML, Jerome KR, et al. Quantitative measurement of infectious virus in SARS-CoV-2 Alpha, Delta and Epsilon variants reveals higher infectivity (viral titer:RNA ratio) in clinical samples containing the Delta and Epsilon variants. medRxiv: 2021.09.07.21263229 [Preprint]. 2021. 10.1101/2021.09.07.21263229.</Citation></Reference><Reference><Citation>Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021;385(7):585–94. 10.1056/NEJMoa2108891.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8314739</ArticleId><ArticleId IdType="pubmed">34289274</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayan M, Arikan A, Isbilen M. In silico evaluation of SARS-CoV-2 K417N, L452R, and E484K detection assays against omicron variants. New Microbiol. 2023;46(2):133–40.</Citation><ArticleIdList><ArticleId IdType="pubmed">37247233</ArticleId></ArticleIdList></Reference><Reference><Citation>Uzun O, Akpolat T, Varol A, Turan S, Bektas SG, Cetinkaya PD, et al. COVID-19: vaccination vs. hospitalization. Infection. 2022;50(3):747–52. 10.1007/s15010-021-01751-1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8725959</ArticleId><ArticleId IdType="pubmed">34984646</ArticleId></ArticleIdList></Reference><Reference><Citation>Marascio N, Cilburunoglu M, Torun EG, Centofanti F, Mataj E, Equestre M, et al. Molecular characterization and cluster analysis of SARS-CoV-2 viral isolates in Kahramanmaraş City, Turkey: the delta VOC wave within one month. Viruses. 2023;15(3):802. 10.3390/v15030802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10054778</ArticleId><ArticleId IdType="pubmed">36992510</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>